Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PABPC1 | P11940 | 2/20 | 0.47 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.47 |
| ▸ | EIF4H | Q15056 | 2/20 | 0.47 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4957912 | 0.81 | HTR2A (0.46) | MEN1KMT2ASMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL904672 | 0.80 | MAPT (0.48) | MEN1KMT2AALDH1A1NPSR1SIRT2 | |
| SCHEMBL4959328 | 0.80 | MAOA (0.43) | MEN1KMT2AGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL7425784 | 0.80 | KMO (0.60) | MAPK1MEN1KMT2AALDH1A1SIRT2 | |
| SCHEMBL7427872 | 0.79 | KMO (0.48) | MEN1KMT2ASMN1; SMN2ALDH1A1NPSR1 | |
| SCHEMBL8684617 | 0.79 | MAOA (0.43) | MEN1KMT2ASMN1; SMN2ALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL8683583 | 0.78 | MAOA (0.42) | MEN1KMT2ASMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL7653557 | 0.78 | MAOA (0.47) | MAPK1MEN1KMT2AGAAALDH1A1 | |
| SCHEMBL8687401 | 0.78 | CYP1A2 (0.50) | MEN1KMT2AGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL3436319 | 0.76 | CCNC (0.49) | MEN1KMT2AALDH1A1SIRT2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332149-B1 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332149-B1 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332149-B1 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-02-19 | — | — | US | disclosed |
| US-7321045-B2 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-01-22 | — | — | US | disclosed |
| US-7321045-B2 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-01-22 | — | — | US | disclosed |
| US-7321045-B2 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1140203-B1 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20050154185-A1 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2005-07-14 | — | — | US | disclosed |
| US-6838074-B2 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-01-04 | — | — | US | disclosed |
| US-20040208823-A1 | SIMULTANEOUS IMAGING OF CARDIAC PERFUSION AND A VITRONECTIN RECEPTOR TARGETED IMAGING AGENT | LANTHEUS MEDICAL IMAGING, INC. | 2004-10-21 | — | — | US | disclosed |
| US-6794518-B1 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-09-21 | — | — | US | disclosed |
| EP-1296678-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS FOR USE IN COMBINATION THERAPY | Bristol-Myers Squibb Pharma Company (US) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001098294-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS FOR USE IN COMBINATION THERAPY | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-12-27 | — | — | WO | disclosed |
| EP-1140203-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000035488-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040208823-A1 | SIMULTANEOUS IMAGING OF CARDIAC PERFUSION AND A VITRONECTIN RECEPTOR TARGETED IMAGING AGENT | TNNI3, ASGR1, TNNT2 | PABPC1 2082/4885APOBEC3A 3945/4885EIF4H 4826/4885 |
| US-20050154185-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, VCAM1 | PABPC1 2776/4885APOBEC3A 4763/4885EIF4H 4787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.